---
title: "Pharmaceutical stocks are repeatedly active, MEDISAN and Rundu Pharma hit the limit up"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/234306303.md"
description: "Pharmaceutical stocks are repeatedly active, with Science Sun Pharm, MEDISAN, and Rundu Pharma hitting the limit up, while ApicHope, DuRui Pharma, and LuKang Pharma also follow suit"
datetime: "2025-04-03T01:40:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/234306303.md)
  - [en](https://longbridge.com/en/news/234306303.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/234306303.md)
generator: "portal-rs"
---

# Pharmaceutical stocks are repeatedly active, MEDISAN and Rundu Pharma hit the limit up

Pharmaceutical stocks are repeatedly active, with Science Sun Pharm, MEDISAN, and Rundu Pharma hitting the limit up, while ApicHope, DuRui Pharma, and LuKang Pharma also saw gains

### Related Stocks

- [300485.CN](https://longbridge.com/en/quote/300485.CN.md)
- [002900.CN](https://longbridge.com/en/quote/002900.CN.md)
- [002923.CN](https://longbridge.com/en/quote/002923.CN.md)
- [300723.CN](https://longbridge.com/en/quote/300723.CN.md)
- [600789.CN](https://longbridge.com/en/quote/600789.CN.md)
- [301075.CN](https://longbridge.com/en/quote/301075.CN.md)

## Related News & Research

- [Golf-PGA Tour overhauls post-season, moving to match play format in 2028](https://longbridge.com/en/news/296930417.md)
- [Haisco Enters Into Exclusive License Agreement With New US Venture Founded By Population Health Partners And ARCH Venture Partners](https://longbridge.com/en/news/296910145.md)
- [Lenzing shareholders approve EUR 300 million capital increase at extraordinary meeting](https://longbridge.com/en/news/296902548.md)
- [LeanDNA Launches Demand Scenario Modeling in APEX, Replacing Spreadsheet Guesswork With Real-Time Production Feasibility](https://longbridge.com/en/news/296950066.md)
- [Cerro de Pasco Resources publishes FY2026 annual report](https://longbridge.com/en/news/296917802.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**